云南白药
(000538)
| 流通市值：985.20亿 | | | 总市值：985.27亿 |
| 流通股本：17.84亿 | | | 总股本：17.84亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 32,257,063,315.53 | 21,884,075,971.15 | 11,602,596,895.18 | 41,186,999,090.31 |
| 营业收入 | 32,257,063,315.53 | 21,884,075,971.15 | 11,602,596,895.18 | 41,186,999,090.31 |
| 二、营业总成本 | 27,521,012,106.28 | 18,422,708,603.11 | 9,475,409,648 | 36,210,224,002.36 |
| 营业成本 | 22,860,962,676.11 | 15,305,914,691.16 | 8,048,363,101.82 | 29,032,923,195.82 |
| 税金及附加 | 182,848,245.14 | 131,037,059.41 | 58,641,693.75 | 234,100,213.88 |
| 销售费用 | 3,632,393,701.52 | 2,450,428,700.94 | 1,149,720,004.51 | 5,619,465,376.89 |
| 管理费用 | 525,840,281.59 | 327,578,033.29 | 130,505,111.34 | 1,020,080,152.22 |
| 研发费用 | 290,580,765.19 | 189,575,115.25 | 76,790,122.07 | 350,545,386.25 |
| 财务费用 | 28,386,436.73 | 18,175,003.06 | 11,389,614.51 | -46,890,322.7 |
| 其中:利息费用 | 12,755,622.52 | 10,236,543.28 | 5,085,418.24 | 24,049,890.09 |
| 其中:利息收入 | 26,037,825.85 | 19,118,451.87 | 10,427,785.54 | 90,467,001.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 125,896,660.94 | 129,325,396.89 | 16,376,374.37 | 110,489,468.71 |
| 加:投资收益 | 786,080,515.65 | 601,930,486 | 242,968,938.97 | 1,042,986,305.52 |
| 资产处置收益 | 1,744,478.56 | 1,111,348.76 | 1,025,221.36 | 8,167,595.81 |
| 资产减值损失(新) | -78,767,544.51 | -24,068,120.33 | -6,621,331.64 | -258,372,158.02 |
| 信用减值损失(新) | -73,939,486.28 | 40,950,070.41 | -71,455,718.12 | 58,066,387.77 |
| 其他收益 | 79,496,839.1 | 63,467,539.93 | 52,104,616.15 | 100,782,693.13 |
| 四、营业利润 | 5,576,562,672.71 | 4,274,084,089.7 | 2,361,585,348.27 | 6,038,895,380.87 |
| 加:营业外收入 | 15,029,182.43 | 13,148,676.97 | 2,967,869.41 | 24,951,555.82 |
| 减:营业外支出 | 18,736,161.7 | 4,675,701.85 | 3,674,264.33 | 20,576,232.96 |
| 五、利润总额 | 5,572,855,693.44 | 4,282,557,064.82 | 2,360,878,953.35 | 6,043,270,703.73 |
| 减:所得税费用 | 753,878,505.15 | 585,309,080.65 | 330,297,748.47 | 853,329,846.75 |
| 六、净利润 | 4,818,977,188.29 | 3,697,247,984.17 | 2,030,581,204.88 | 5,189,940,856.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,818,977,188.29 | 3,697,247,984.17 | 2,030,581,204.88 | 5,189,940,856.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,822,353,319.2 | 3,701,170,618.67 | 2,037,306,990.13 | 5,153,486,838.91 |
| 少数股东损益 | -3,376,130.91 | -3,922,634.5 | -6,725,785.25 | 36,454,018.07 |
| 扣除非经常损益后的净利润 | 4,630,906,875.24 | 3,518,415,542.36 | 1,965,172,511.31 | 4,864,568,403.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 2.7 | 2.07 | 1.14 | 2.89 |
| (二)稀释每股收益 | 2.7 | 2.07 | 1.14 | 2.89 |
| 八、其他综合收益 | -12,773,815.9 | -15,517,150.66 | -8,785,384.58 | -6,013,856.89 |
| 归属于母公司股东的其他综合收益 | -9,215,988.64 | -12,557,502.52 | -6,965,862.49 | -3,828,024.2 |
| 九、综合收益总额 | 4,806,203,372.39 | 3,681,730,833.51 | 2,021,795,820.3 | 5,183,927,000.09 |
| 归属于母公司股东的综合收益总额 | 4,813,137,330.56 | 3,688,613,116.15 | 2,030,341,127.64 | 5,149,658,814.71 |
| 归属于少数股东的综合收益总额 | -6,933,958.17 | -6,882,282.64 | -8,545,307.34 | 34,268,185.38 |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-30 | 2026-04-01 |
| 审计意见(境内) | | | | 标准无保留意见 |